Literature DB >> 23393672

Impairment of immune systems in diabetes.

Christopher Ting1, Vivek Bansal, Ibrahim Batal, Marwan Mounayar, Lola Chabtini, Ghania El Akiki, Jamil Azzi.   

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease that involves the progressive destruction of the insulin-producing beta cells in the islets of langerhans. It is a complex process that results from the loss of tolerance to insulin and other beta-cell-specific antigens. Various genetic and environmental factors have been studied so far, but precise causation has yet to be established. Numerous studies in rodents and human subjects have been performed in order to elucidate the role of B and T cells, which determine the risk of development and progression of diabetes. These studies have demonstrated that while T1DM is fundamentally a T-cell-mediated autoimmune response, the development of this disease results from complex interactions between the adaptive and innate immune systems, with numerous cell types thought to contribute to pathogenesis. Like any complex disease, the variation in severity and incidence of T1DM can be attributed to a combination of genetic and environmental factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23393672     DOI: 10.1007/978-1-4614-5441-0_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Co-occurrence of opisthorchiasis and diabetes exacerbates morbidity of the hepatobiliary tract disease.

Authors:  Apisit Chaidee; Sudarat Onsurathum; Kitti Intuyod; Patchareewan Pannangpetch; Chatlert Pongchaiyakul; Porntip Pinlaor; Chawalit Pairojkul; Wannaporn Ittiprasert; Christina J Cochran; Victoria H Mann; Paul J Brindley; Somchai Pinlaor
Journal:  PLoS Negl Trop Dis       Date:  2018-06-28

2.  Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development.

Authors:  Katarzyna Siewko; Rafal Maciulewski; Anna Zielinska-Maciulewska; Anna Poplawska-Kita; Piotr Szumowski; Natalia Wawrusiewicz-Kurylonek; Danuta Lipinska; Robert Milewski; Maria Gorska; Adam Kretowski; Malgorzata Szelachowska
Journal:  Biomed Res Int       Date:  2019-10-20       Impact factor: 3.411

3.  Hsa_circ_0060450 Negatively Regulates Type I Interferon-Induced Inflammation by Serving as miR-199a-5p Sponge in Type 1 Diabetes Mellitus.

Authors:  Lan Yang; Xiao Han; Caiyan Zhang; Chengjun Sun; Saihua Huang; Wenfeng Xiao; Yajing Gao; Qiuyan Liang; Feihong Luo; Wei Lu; Jinrong Fu; Yufeng Zhou
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

4.  Decreased interleukin-35 levels and CD4+EBI3+ T cells in patients with type 1 diabetes and the effects of the antibody against CD20 (rituximab).

Authors:  Han Ouyang; Jian Wen; Kai Song
Journal:  Arch Med Sci       Date:  2020-12-04       Impact factor: 3.318

5.  Impaired Innate Immunity in Pediatric Patients Type 1 Diabetes-Focus on Toll-like Receptors Expression.

Authors:  Katarzyna Kurianowicz; Maria Klatka; Agnieszka Polak; Anna Hymos; Dominika Bębnowska; Martyna Podgajna; Rafał Hrynkiewicz; Olga Sierawska; Paulina Niedźwiedzka-Rystwej
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

6.  Glibenclamide attenuates myocardial injury by lipopolysaccharides in streptozotocin-induced diabetic mice.

Authors:  Jian Cai; Shuai Lu; Zheng Yao; Ya-Ping Deng; Ling-Di Zhang; Jia-Wen Yu; Guo-Fei Ren; Fu-Ming Shen; Guo-Jun Jiang
Journal:  Cardiovasc Diabetol       Date:  2014-07-31       Impact factor: 9.951

7.  Excess cost burden of diabetes in Southern India: a clinic-based, comparative cost-of-illness study.

Authors:  K M Sharma; H Ranjani; A Zabetian; M Datta; M Deepa; C R Anand Moses; K M V Narayan; V Mohan; M K Ali
Journal:  Glob Health Epidemiol Genom       Date:  2016-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.